Bibliography
- Gandhi PN, Chen SG, Wilson-Delfosse AL. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. J Neurosci Res 2009;87(6):1283-95
- Dorsey ER, Constantinescu R, Thompson JP, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68(5):384-6
- Daniels V, Baekelandt V, Taymans JM. On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies. Neuro-Signals 2011;19(1):1-15
- Dächsel JC, Farrer MJ. LRRK2 and Parkinson disease. Arch Neurol 2010;67(5):542-7
- Kumar A, Cookson MR. Role of LRRK2 kinase dysfunction in Parkinson disease. Expert Rev Mol Med 2011;13:e20
- Kramer T, Lo Monte F, Goring S, Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's Disease models. ACS Chem Neurosci 2012;3(3):151-60
- Covy JP, Giasson BI. Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2. Biochem Biophys Res Commun 2009;378(3):473-7
- Lee BD, Shin JH, VanKampen J, Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 2010;16(9):998-1000
- Ramsden N, Perrin J, Ren Z, Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol 2011;6(10):1021-8
- Zhang J, Deng X, Choi HG, Characterization of TAE684 as a potent LRRK2 kinase inhibitor. Bioorg Med Chem Lett 2012;22(5):1864-9
- Deng X, Dzamko N, Prescott A, Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2. Nat Chem Biol 2011;7(4):203-5
- Medical Research Council Technology, UK. Preparation of pyrazolopyridine compounds as kinase inhibitors patent. WO2010106333A1; 2010
- Medical Research Council Technology, UK. Preparation of pyrazolopyridines as kinase LRRK2 inhibitors for treating and preventing cancer and neurodegenerative diseases. WO2011141756A1; 2011
- Aventis Pharma S.A., Fr. Preparation of substituted pyrazolopyridines as kinase inhibitors, and their compositions and use for treatment of cancer. WO2006077319A1; 2006
- Intellikine, Inc., USA. Preparation of pyrazolopyridines as protein and lipid kinase inhibitors. WO2009114870A2; 2009
- Bristol-Myers Squibb Co., USA. Azaindazoles as Btk kinase modulators and their preparation. WO2011019780A1; 2011
- Wager TT, Hou X, Verhoest PR, Villalobos A. Moving beyond rules: the development of a Central Nervous System Multiparameter Optimization (CNS MPO) approach to enable alignment of druglike properties. ACS Chem Neurosci 2010;1(6):435-49
- Chambers JW, Pachori A, Howard S, Small molecule c-jun-N-terminal kinase inhibitors protect dopaminergic neurons in a model of Parkinson's disease. ACS Chem Neurosci 2011;2(4):198-206